Mastering α-Synuclein Biomarkers Across Fluid & Imaging Modalities to Accelerate Parkinson’s Disease Drug Development
9:00 am - Monday 30th November 2026
Gain comprehensive expertise in the most transformative biomarker class for synucleinopathies. This intensive workshop delivers practical knowledge on seed amplification assays, novel PET tracers, and plasma-based detection methods, enabling you to design robust biomarker strategies that de-risk your PD, MSA, and Lewy body dementia programmes. Learn standardisation protocols, compare vendor platforms, and understand regulatory pathways to confidently implement α-synuclein biomarkers from Phase 1 through registration trials.
Key Questions to be Answered:
- How do you establish standardisation protocols for α-synuclein seed amplification assays with different labs and vendors yielding different results, and what harmonisation strategies ensure reproducible outcomes across multiple sites?
- What are the key differences between α-synuclein detection methods, seed amplification assays in CSF and skin biopsies versus novel PET tracers versus plasma-based assays and when should you prioritise each modality based on your trial design, patient population, and mechanism of action?
- How do you validate that α-synuclein biomarkers accurately reflect brain pathology and disease progression, and what evidence is required to use them as eligibility criteria, pharmacodynamic endpoints, or surrogate markers in regulatory submissions?
- How do you integrate α-synuclein fluid biomarkers with PET imaging to create multimodal strategies that provide convergent evidence of target engagement and disease modification, and what are the operational challenges of combining these modalities?
- What are the current limitations of α-synuclein biomarkers, peripheral contamination in blood, lack of correlation with clinical outcomes, unclear relationship to disease subtypes and how do leading programmes address these challenges to build regulatory-grade validation packages?
